ACETYLATOR PHENOTYPE (AP) IN CHILDREN GIVEN SULFISOXAZOLE (SSZ) USING A MULTICOMPARTMENT PHARMACOKINETIC (PK) MODEL

被引：0
|
作者：
DOUIDAR, SM
DODGE, WF
SNODGRASS, WR
机构：
[1] TEXAS TECH UNIV,HLTH SCI CTR,DEPT PEDIAT,DIV CLIN PHARMACOL,AMARILLO,TX
[2] UNIV TEXAS,MED BRANCH,DEPT PEDIAT,GALVESTON,TX 77550
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 1992年 / 51卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：162 / 162
页数：1
相关论文
共 38 条
  • [1] Population PK of IFF and its DCE metabolites in children using an enantiospecific PK model
    Ducharme, MP
    Bernstein, ML
    Granvil, CP
    Wainer, IW
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (02) : OIII3 - OIII3
  • [2] Development of a pharmacokinetic (PK) model and assessment of patient (pt) covariate effects on dose-dependent PK following different dosing schedules in two phase I trials of AP23573 (AP), a mTOR inhibitor.
    Desai, AA
    Mita, M
    Fetterly, GJ
    Chang, C
    Netsch, M
    Knowles, HL
    Bedrosian, CL
    Rowinsky, E
    Tolcher, AW
    Ratain, MJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 202S - 202S
  • [3] Estimating CSF topotecan exposure in children with high-risk meduloblastoma and supratentorial primitive neuroectodermal, tumor (PNET) using a pharmacokinetic (PK) model
    Freeman, BB
    Iacono, LC
    Panetta, JC
    Gajjar, A
    Chintagumpala, M
    Kellic, SJ
    Ashley, D
    Houghton, PJ
    Stewart, CF
    NEURO-ONCOLOGY, 2004, 6 (04) : 428 - 428
  • [4] A compatibility evaluation between the physiologically based pharmacokinetic (PBPK) model and the compartmental PK model using the lumping method with real cases
    Ryu, Hyo-jeong
    Kang, Won-ho
    Kim, Taeheon
    Kim, Jae Kyoung
    Shin, Kwang-Hee
    Chae, Jung-woo
    Yun, Hwi-yeol
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [5] EVALUATION OF THE PHYSIOLOGY-BASED PHARMACOKINETIC (PBPK) MODEL PK-SIM® IN CHILDREN RECEIVING HIGH-DOSE METHOTREXATE
    Adam, K.
    Schmiedl, S.
    Szymanski, J.
    Imschweiler, T.
    Voelpel, S.
    Niehues, T.
    Sinha, K.
    Wirth, S.
    Abu Hejleh, A.
    Willmann, S.
    Lippert, J.
    Thuermann, P. A.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 : 129 - 130
  • [6] A population pharmacokinetic (pop-PK) model of steady-state (SS) paroxetine (PXT) in depressed children (C) and adolescents (A).
    Reed, MD
    Findling, RL
    Capparelli, EV
    O'Riordan, MA
    Blumer, JL
    JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (09): : 1028 - 1028
  • [7] EVALUATION OF THE PHYSIOLOGY-BASED PHARMACOKINETIC (PBPK) MODEL PK-SIM® IN CHILDREN RECEIVING HIGH-DOSE METHOTREXATE
    Adam, K.
    Schmiedl, S.
    Szymanski, J.
    Imschweiler, T.
    Voelpel, S.
    Niehues, T.
    Sinha, K.
    Wirth, S.
    Abu Hejleh, A.
    Samayoa, P.
    Willmann, S.
    Lippert, J.
    Thuermann, P. A.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 : 13 - 13
  • [8] Improving cefazolin exposure in critically ill children using a population pharmacokinetic model
    Rivaud, Clemence
    Oualha, Mehdi
    Salvador, Elodie
    Bille, Emmanuelle
    Callot, Delphine
    Beranger, Agathe
    Bournaud, Leo Froelicher
    Rouillon, Steeve
    Toubiana, Julie
    Benaboud, Sihem
    Renolleau, Sylvain
    Treluyer, Jean Marc
    Hirt, Deborah
    de Cacqueray, Noemie
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024,
  • [9] Predicting tacrolimus concentrations in children receiving a heart transplant using a population pharmacokinetic model
    Rower, Joseph E.
    Stockmann, Chris
    Linakis, Matthew W.
    Kumar, Shaun S.
    Liu, Xiaoxi
    Korgenski, E. Kent
    Sherwin, Catherine M. T.
    Molina, Kimberly M.
    BMJ PAEDIATRICS OPEN, 2017, 1 (01)
  • [10] Retraction Note: Characterization of Preclinical Pharmacokinetic Properties and Prediction of Human PK Using a Physiologically Based Pharmacokinetic Model for a Novel Anti-Arrhythmic Agent Sulcardine Sulfate
    Chang Ren
    Yao Wang
    Mei Zhang
    Dexuan Kong
    Chen Ning
    Yujie Cheng
    Yueying Bian
    Mengqi Sun
    Shengdi Su
    Yucong Wang
    Yongjie Zhang
    Yang Lu
    Ning Li
    Di Zhao
    Xijing Chen
    Pharmaceutical Research, 2023, 40 : 1311 - 1311
1234